

# Prevention by vaccination: the economics of vaccination programmes

John Edmunds<sup>1,2</sup>

<sup>1</sup> PHLS CDSC

Colindale, London

<sup>2</sup> Dept. Economics

City University, London


# Introduction

- Infectious diseases are different
  - They are infectious
- Interventions aimed at preventing or treating disease in one individual has knock-on effects on others in the population
  - Externalities (both positive **and negative**)
  - Free-loader problem as all vaccine carry some risk
  - Equity: affect distribution of disease

# Structure of talk

- Simple relationship between infection & disease
  - Epidemic theory
  - Demand for vaccines
    - As a function of prevalence, and/or risk of adverse events
  - Observational data
    - Response to vaccine scares
  - Empirical studies
- Complex relationship between infection & disease
  - Equity considerations

# A simple epidemic (SIR) model



$$N_t = S_t + I_t + R_t$$

$$dS/dt = \mu N(1-v) - \beta I S - \mu S$$

$$dI/dt = \beta I S - \mu I - \gamma I$$

$$dR/dt = \gamma I - \mu R + \mu N v$$

Geoffard & Philipson:  $V_t(I_t, p_t)$

# Threshold for persistence

$dI/dt = 0 =$  endemic equilibrium (for  $I > 0$ )

$$S^* \beta / (\gamma + \mu) = 1$$

- If maintain  $S_t < S^*$  (by vaccination) then infection cannot persist in the population
- I.e. **threshold for elimination,  $P_c \geq 1 - S^*$**


# Geoffard & Philipson

- Central assumption is that demand for prevention is prevalence dependent  $V_t(I^t, p^t)$
- As prevalence of disease falls, then demand for vaccine falls
- Result: increase in disease
- Very difficult (impossible) to eradicate
  - regardless of market structure (demand problem)
  - Pigovian price subsidies may not be sufficient
  - Mandatory vaccination decreases incentive for others (outside) programme to vaccinate

# Modification:



*demand a function of perceived risk of vaccine*

- Risk from vaccine remains unchanged
- Risk from natural infection declines
- Therefore benefit:risk ratio (to individuals) decreases
- Difficult to eliminate
- Qualitatively similar to Geoffard & Philipson



# Demand as a function of risk


## Example: lifetime risk based on current risk




# Is demand prevalence / risk dependent?

- Observational studies
  - Geoffard & Philipson MMR vaccination in the US 1984-1991: regional caseload has large positive impact on hazard rate into vaccination (most influential explanatory variable)
  - Diphtheria – Tetanus – Pertussis vaccine in UK
  - MMR in the UK
- Empirical studies

# Whooping cough & diphtheria notifications & vaccine coverage England and Wales, 1940-97




# Annual measles notifications & vaccine coverage *England and Wales 1950-1997*



Source: Office for National Statistics and Department of Health


# Mothers beliefs of vaccine safety

*HEA survey 1994-8*



# MMR vaccine coverage at 16 and 24 months

*(English districts/trusts using the NCHS)*



# Demand as a function of risk?

WTP (£) for varicella vaccination: pilot survey

	100% risk	50% risk	25% risk
Median wtp	88	88	88
Mean wtp	109	97	102
St Dev	61	79	79
n	16	16	16

# Demand for vaccines: summary

- Demand for vaccines is probably a function of expected future incidence of disease & perceived risk of the vaccine (& other factors)
  - Either renders elimination difficult (though achieved)
- Possibly more sensitive to perceived risk of vaccine than (future) prevalence of disease
  - Possible imbalance in demand relationship due to memory
- Demand fairly inelastic regarding risk (assuming no substitute goods)
- Implications:
  - Coverage remains high when incidence low
  - Vaccine scares can affect coverage
  - Education regarding true risk of vaccines critical


# Risk of vaccination *programmes*

- Often the probability of disease given infection is related to factors such as age
- Many viral infections are more severe if contacted during adulthood:
  - Chickenpox, polio, mumps, HAV, rubella

# Effects of mass (childhood) immunisation

- Direct protection
  - Individual vaccinees are protected
- Increased susceptibles in older age groups
- Increased average age at infection
  - Temporal (vaccinees are in the younger age-groups)
  - Long-term (due to reduced probability of infection)


# An age-structured epidemic model



$$\lambda_i(t) = \sum \beta_{ij} I_j(t)$$

# Predicted long term incidence of CRS in the UK


## Selective and universal vaccination programmes



following Anderson & Grenfell, 1986

# Predicted long term incidence of CRS in the UK

## Universal vaccination programmes



# Risks of vaccination programmes

- Risk to individual may **increase** with **increasing** uptake of the vaccine, then fall
- Low / intermediate coverage often results from “free market” supply of vaccines
- Can reduce health of the population (short and long-run)
- Can lead to dramatic increase in inequalities
- Such risks can be difficult to portray to decision makers